PMID- 20029203
OWN - NLM
STAT- MEDLINE
DCOM- 20100520
LR  - 20181201
IS  - 1421-9867 (Electronic)
IS  - 0012-2823 (Linking)
VI  - 81
IP  - 1
DP  - 2010
TI  - Current standings of the proton pump inhibitor and clopidogrel co-therapy: review 
      on an evolving field with the eyes of the gastroenterologist.
PG  - 10-5
LID - 10.1159/000243717 [doi]
AB  - The negative effect of proton pump inhibitors (PPI) on the antiplatelet function 
      of clopidogrel has only recently emerged on the horizon of cardiological 
      interest. To date, one can only find 10 peer-reviewed papers on PubMed on this 
      issue, although the increasing activity is unquestionable. Besides publications, 
      conference reports and official web sites are therefore important sources of 
      information. In this field, the first step was made by an experimental study 
      proving the adverse effect of omeprazole on clopidogrel function. Consequently, 
      retrospective studies reported a significant increase of major adverse 
      cardiovascular events among patients taking the combination of omeprazole and 
      clopidogrel. Based on the paucity of quality data and limitations of studies 
      conducted on this interaction, some are still reluctant to confirm the pathogenic 
      role of PPI and clopidogrel interaction in the development of reinfarctions. One 
      step further ahead, admitting the risks related to the combination of these two 
      drugs, the next question to be decided is whether we face a class effect, or 
      thanks to the different metabolic pathways there are indeed relevant differences 
      among PPIs. There is a lot at stake, since the volume of patients taking the dual 
      aspirin-clopidogrel antiplatelet therapy and thereby needing gastroprotection is 
      immense, rendering a huge responsibility to the societies and committees who are 
      making proposals on the selection of appropriate PPIs.
CI  - Copyright 2009 S. Karger AG, Basel.
FAU - Juhasz, Mark
AU  - Juhasz M
AD  - 2nd Department of Medicine, Semmelweis University, Budapest, Hungary. 
      juhaszmarkdr@gmail.com
FAU - Herszenyi, Laszlo
AU  - Herszenyi L
FAU - Tulassay, Zsolt
AU  - Tulassay Z
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20091222
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
RN  - KG60484QX9 (Omeprazole)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Acute Coronary Syndrome/therapy
MH  - Angioplasty, Balloon, Coronary
MH  - Aspirin/adverse effects/therapeutic use
MH  - Clopidogrel
MH  - Drug Interactions
MH  - Drug Therapy, Combination/adverse effects
MH  - Gastroenterology/*trends
MH  - Gastrointestinal Hemorrhage/chemically induced/prevention & control
MH  - Humans
MH  - Myocardial Infarction/chemically induced
MH  - Omeprazole/adverse effects/therapeutic use
MH  - Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
MH  - Proton Pump Inhibitors/*adverse effects/therapeutic use
MH  - Recurrence
MH  - Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use
RF  - 16
EDAT- 2009/12/24 06:00
MHDA- 2010/05/21 06:00
CRDT- 2009/12/24 06:00
PHST- 2009/12/24 06:00 [entrez]
PHST- 2009/12/24 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
AID - 000243717 [pii]
AID - 10.1159/000243717 [doi]
PST - ppublish
SO  - Digestion. 2010;81(1):10-5. doi: 10.1159/000243717. Epub 2009 Dec 22.